Home / Innere Medizin / Onkologie / ASCO 2019: Neue Optionen bei EGFR-, MET- und RET-Mutationen
Metastasiertes NSCLC

ASCO 2019: Neue Optionen bei EGFR-, MET- und RET-Mutationen

OA Dr. Maximilian J. Hochmair, Pneumologie, Krankenhaus Nord, Wien, über neue Therapien beim metastasierten Lungenkarzinom sowie Erfreuliches für Autoimmun-Patienten mit Immuntherapie.

Abstracts, die in diesem Video diskutiert werden:

  • Nakagawa K et al. RELAY: A multinational, double-blind, randomized Phase 3 study of erlotinib (ERL) in combination with ramucirumab (RAM) or placebo (PL) in previously untreated patients with epidermal growth factor receptor mutation-positive (EGFRm) metastatic non-small cell lung cancer (NSCLC). Abstract 9000
  • Noronha V et al. Phase III randomized trial comparing gefitinib to gefitinib with pemetrexed-carboplatin chemotherapy in patients with advanced untreated EGFR mutant non-small cell lung cancer (gef vs gef+C). Abstract 9001
  • Janne PA et al. Antitumor activity of TAK-788 in NSCLC with EGFR exon 20 insertions. Abstract 9007
  • Paik PK et al. Phase II study of tepotinib in NSCLC patients with METex14 mutations. Abstract 9005
  • Gainor JF et al. Clinical activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients (pts) with advanced RET-fusion+ non-small cell lung cancer (NSCLC). Abstract 9008
  • Khozin S et al. Real-world characteristics and outcomes of patients with advanced non-small cell lung cancer (aNSCLC) receiving immune checkpoint inhibitor. Abstract 9110
LOGIN

Login

Passwort vergessen?